Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STR-50
- Development stage
- Preclinical
- Lead developer
- Starget Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
STR-50 is a pan-somatostatin receptor (SSTR) targeting radiopharmaceutical theranostic being developed by Starget Pharma. It is designed for both the diagnostic imaging and therapeutic treatment of neuroendocrine tumors (NET). Unlike many existing SSTR-targeted agents that primarily target the SSTR2 subtype, STR-50 is engineered to bind across multiple SSTR subtypes (pan-SSTR), potentially providing a more comprehensive approach for tumors with heterogeneous receptor expression. The program is currently in the IND-enabling stage of development.
- Other names
- STR-50 TheranosticSTR50 TheranosticSTR 50 Theranostic
02
Targets
SSTR3 (Somatostatin receptor 3)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on STR-50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STR-50.